RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pathfinder Cell Therapy Stock

Pathfinder Cell Therapy EBIT 2024

Pathfinder Cell Therapy EBIT

-1.12 M USD

Ticker

PFND

ISIN

US70319A1060

WKN

A0EAT6

In 2024, Pathfinder Cell Therapy's EBIT was -1.12 M USD, a -30.02% increase from the -1.6 M USD EBIT recorded in the previous year.

The Pathfinder Cell Therapy EBIT history

YEAREBIT (undefined USD)
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-
2004-
2003-
2002-
2001-
2000-
1999-
1998-
1997-
1996-
1995-

Pathfinder Cell Therapy Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pathfinder Cell Therapy, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pathfinder Cell Therapy from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pathfinder Cell Therapy’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pathfinder Cell Therapy. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pathfinder Cell Therapy’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pathfinder Cell Therapy’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pathfinder Cell Therapy’s growth potential.

Pathfinder Cell Therapy Revenue, EBIT and net profit per share

DatePathfinder Cell Therapy RevenuePathfinder Cell Therapy EBITPathfinder Cell Therapy Net Income
20140 undefined-1.12 M undefined-1.39 M undefined
201354,000 undefined-1.6 M undefined-1.71 M undefined
2012114,000 undefined-2.06 M undefined-2.16 M undefined
201173,000 undefined-3.62 M undefined-11.27 M undefined
20100 undefined-827,000 undefined-1.29 M undefined
2009360,000 undefined-4.12 M undefined-4.1 M undefined
2008180,000 undefined-4.58 M undefined-4.4 M undefined
2007130,000 undefined-5.35 M undefined-4.62 M undefined
2006140,000 undefined-4.54 M undefined-3.9 M undefined
20050 undefined-2.46 M undefined-2.15 M undefined
200420,000 undefined-2.38 M undefined-1.92 M undefined
200330,000 undefined-2.02 M undefined-1.9 M undefined
200230,000 undefined-1.28 M undefined-1.47 M undefined
200140,000 undefined-1.07 M undefined-730,000 undefined
2000100,000 undefined-1 M undefined-520,000 undefined
19991.25 M undefined-2.22 M undefined-960,000 undefined
19981.77 M undefined-7.76 M undefined-7.6 M undefined
199760,000 undefined-8.22 M undefined-7.67 M undefined
1996160,000 undefined-4.37 M undefined-3.83 M undefined
1995250,000 undefined-2.98 M undefined-2.8 M undefined

Pathfinder Cell Therapy stock margins

The Pathfinder Cell Therapy margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pathfinder Cell Therapy. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pathfinder Cell Therapy.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pathfinder Cell Therapy's sales revenue. A higher gross margin percentage indicates that the Pathfinder Cell Therapy retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pathfinder Cell Therapy's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pathfinder Cell Therapy's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pathfinder Cell Therapy's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pathfinder Cell Therapy. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pathfinder Cell Therapy's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pathfinder Cell Therapy Margin History

Pathfinder Cell Therapy Gross marginPathfinder Cell Therapy Profit marginPathfinder Cell Therapy EBIT marginPathfinder Cell Therapy Profit margin
201431.48 %0 %0 %
201331.48 %-2,961.11 %-3,157.41 %
201256.14 %-1,807.02 %-1,891.23 %
201164.38 %-4,956.16 %-15,438.36 %
201031.48 %0 %0 %
200954.44 %-1,144.44 %-1,139.72 %
200844.44 %-2,544.44 %-2,444.44 %
200784.62 %-4,115.38 %-3,553.85 %
200685.71 %-3,242.86 %-2,785.71 %
200531.48 %0 %0 %
200431.48 %-11,900 %-9,600 %
200331.48 %-6,733.33 %-6,333.33 %
200231.48 %-4,266.67 %-4,900 %
2001100 %-2,675 %-1,825 %
2000100 %-1,000 %-520 %
199955.2 %-177.6 %-76.8 %
199853.67 %-438.42 %-429.38 %
1997100 %-13,700 %-12,783.33 %
1996100 %-2,731.25 %-2,393.75 %
1995100 %-1,192 %-1,120 %

Pathfinder Cell Therapy Aktienanalyse

What does Pathfinder Cell Therapy do?

Pathfinder Cell Therapy Inc is a biopharmaceutical company specializing in the development of cell-based therapies. The company was founded in 2018 and is headquartered in Boston, Massachusetts. The founders of Pathfinder Cell Therapy have come together to develop innovative solutions for diseases that cannot be treated by conventional therapies. They believe that cell-based therapies have the potential to dramatically improve the lives of patients by directly addressing the underlying causes of their diseases. Pathfinder Cell Therapy's business model focuses on the development of cell-based therapies for specific diseases. The company works closely with academics, scientists, and clinicians to incorporate the latest knowledge and technologies into the development of new therapies. Pathfinder Cell Therapy has various divisions that focus on the development of cell-based therapies for specific diseases. One focus is on developing therapies for rare genetic diseases that are often difficult to treat. Other divisions focus on the development of therapies for cancer and autoimmune diseases. The company already has several products in development, including a cell-based therapy for the treatment of mucopolysaccharidosis type I (MPS-I), a rare genetic disease in which a specific type of sugar cannot be broken down and accumulates in various organs. Pathfinder Cell Therapy also plans to develop cell-based therapies for other rare genetic diseases such as Fabry disease and Krabbe disease. Another important product of Pathfinder Cell Therapy is a cell-based therapy for the treatment of certain types of cancer. This therapy harnesses the ability of immune cells to recognize and attack cancer cells to mobilize the body in the fight against cancer. This type of therapy is called immunotherapy and has made significant advances in recent years. Pathfinder Cell Therapy is also working on the development of cell-based therapies for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In these diseases, the immune system mistakenly attacks healthy body cells. Cell-based therapies can help reprogram the immune system to only target pathogens and leave healthy cells unharmed. Overall, Pathfinder Cell Therapy aims to develop the next generation of cell-based therapies to treat diseases that have been difficult or impossible to treat in the past. The company has an experienced team of scientists who work closely with doctors and patients to ensure that their therapies can truly improve people's lives. Pathfinder Cell Therapy is still in the development phase, but the company has already made promising progress and is expected to achieve further success in the coming years. Pathfinder Cell Therapy ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Pathfinder Cell Therapy's EBIT

Pathfinder Cell Therapy's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pathfinder Cell Therapy's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pathfinder Cell Therapy's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pathfinder Cell Therapy’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pathfinder Cell Therapy stock

How much did Pathfinder Cell Therapy achieve in EBIT for the current year?

In the current year, Pathfinder Cell Therapy has achieved an EBIT of -1.12 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Pathfinder Cell Therapy.

How has the EBIT of Pathfinder Cell Therapy developed in recent years?

The EBIT of Pathfinder Cell Therapy has increased by -30.019% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Pathfinder Cell Therapy?

The EBIT of Pathfinder Cell Therapy is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Pathfinder Cell Therapy pay?

Over the past 12 months, Pathfinder Cell Therapy paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pathfinder Cell Therapy is expected to pay a dividend of 0 USD.

What is the dividend yield of Pathfinder Cell Therapy?

The current dividend yield of Pathfinder Cell Therapy is .

When does Pathfinder Cell Therapy pay dividends?

Pathfinder Cell Therapy pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pathfinder Cell Therapy?

Pathfinder Cell Therapy paid dividends every year for the past 0 years.

What is the dividend of Pathfinder Cell Therapy?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pathfinder Cell Therapy located?

Pathfinder Cell Therapy is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pathfinder Cell Therapy kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pathfinder Cell Therapy from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Pathfinder Cell Therapy pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Pathfinder Cell Therapy in the year 2023?

In the year 2023, Pathfinder Cell Therapy distributed 0 USD as dividends.

In which currency does Pathfinder Cell Therapy pay out the dividend?

The dividends of Pathfinder Cell Therapy are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pathfinder Cell Therapy

Our stock analysis for Pathfinder Cell Therapy Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pathfinder Cell Therapy Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.